Invenra raises $3M to develop antibodies with, and for, drug makers

By Jeff Buchanan, Xconomy

invenra_logo_3d_webMadison, WI-based Invenra has raised more than $3 million from 27 investors, according to a document filed with federal securities regulators.

Mark Kubik, the company’s vice president of business development, says that some of the money will go toward fulfilling agreements it’s made with drug companies, including U.K.-based Oxford BioTherapeutics, which Invenra announced it had partnered with last year.

Invenra’s cell-free protein expression technology allows for the screening of hundreds of thousands of full antibodies, and is much faster than conventional cell-based methods for finding therapeutic antibodies.

The company’s core business model involves licensing its technology to drug makers, Kubik says. With these deals, the pharmaceutical partner owns and is responsible for developing the antibody products. Read more …

Comments are closed.
Facebook IconYouTube IconTwitter IconVisit Our LinkedIn Profile